256 related articles for article (PubMed ID: 31372961)
1. Usability of Prefilled Syringe and Autoinjector for SB4 (An Etanercept Biosimilar) in Patients with Rheumatoid Arthritis.
Rho YH; Rychlewska-Hańczewska A; Śliwowska B; Kim TH
Adv Ther; 2019 Sep; 36(9):2287-2295. PubMed ID: 31372961
[TBL] [Abstract][Full Text] [Related]
2. Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis.
Ghil J; Zielińska A; Lee Y
Curr Med Res Opin; 2019 Mar; 35(3):497-502. PubMed ID: 30561229
[TBL] [Abstract][Full Text] [Related]
3. Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE
Cohen S; Klimiuk PA; Krahnke T; Assudani D
Expert Opin Drug Deliv; 2018 Jun; 15(6):545-548. PubMed ID: 29764238
[TBL] [Abstract][Full Text] [Related]
4. GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.
von Richter O; Skerjanec A; Afonso M; Sanguino Heinrich S; Poetzl J; Woehling H; Velinova M; Koch A; Kollins D; Macke L; Wuerth G
Br J Clin Pharmacol; 2017 Apr; 83(4):732-741. PubMed ID: 27790726
[TBL] [Abstract][Full Text] [Related]
5. Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study.
Girolomoni G; Feldman SR; Emery P; Ghil J; Keum JW; Cheong SY; Hong E
Br J Dermatol; 2018 Mar; 178(3):e215-e216. PubMed ID: 29023641
[No Abstract] [Full Text] [Related]
6. Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects.
Shin D; Kim Y; Go A; Velinova M
Drug Des Devel Ther; 2020; 14():43-50. PubMed ID: 32021090
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male Participants.
Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
Adv Ther; 2023 Nov; 40(11):4889-4906. PubMed ID: 37707674
[TBL] [Abstract][Full Text] [Related]
8. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.
Emery P; Vencovský J; Sylwestrzak A; Leszczyński P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
Ann Rheum Dis; 2017 Jan; 76(1):51-57. PubMed ID: 26150601
[TBL] [Abstract][Full Text] [Related]
9. A novel electromechanical autoinjector, AutoTouch™, for self-injection of etanercept: real-world use and benefits.
Collier DH; Bitman B; Coles A; Liu L; Kumar S; Judd C
Postgrad Med; 2017 Jan; 129(1):118-125. PubMed ID: 27829325
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis - A comparison in a real-world national cohort.
Codreanu C; Popescu CC; Mogoșan C; Enache L; Daia S; Ionescu R; Opriș-Belinski D
Biologicals; 2019 Nov; 62():27-32. PubMed ID: 31668853
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data.
Atzeni F; Gerratana E; Bongiovanni S; Talotta R; Miceli G; Salaffi F; Sarzi-Puttini P
Isr Med Assoc J; 2021 Jun; 23(6):344-349. PubMed ID: 34155846
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects.
Shin D; Lee Y; Jeong D; Ellis-Pegler R
Drug Des Devel Ther; 2018; 12():3799-3805. PubMed ID: 30464411
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects.
Lee YJ; Shin D; Kim Y; Kang J; Gauliard A; Fuhr R
Br J Clin Pharmacol; 2016 Jul; 82(1):64-73. PubMed ID: 26972584
[TBL] [Abstract][Full Text] [Related]
14. Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study.
Pope J; Hall S; Bombardier C; Haraoui B; Jones G; Naik L; Etzel CJ; Ramey DR; Infante R; Miguelez M; Falcao S; Sahakian S; Wu D
Adv Ther; 2022 Nov; 39(11):5259-5273. PubMed ID: 36136243
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Persistence in SB4- and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway.
Haugeberg G; Bakland G; Rødevand E; Hansen IJW; Diamantopoulos A; Pripp AH
Arthritis Care Res (Hoboken); 2023 Sep; 75(9):1986-1995. PubMed ID: 36722450
[TBL] [Abstract][Full Text] [Related]
16. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
Emery P; Vencovský J; Sylwestrzak A; Leszczynski P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
Rheumatology (Oxford); 2017 Dec; 56(12):2093-2101. PubMed ID: 28968793
[TBL] [Abstract][Full Text] [Related]
17. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study.
Tweehuysen L; Huiskes VJB; van den Bemt BJF; Vriezekolk JE; Teerenstra S; van den Hoogen FHJ; van den Ende CH; den Broeder AA
Arthritis Rheumatol; 2018 Sep; 70(9):1408-1418. PubMed ID: 29609207
[TBL] [Abstract][Full Text] [Related]
18. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
Glintborg B; Loft AG; Omerovic E; Hendricks O; Linauskas A; Espesen J; Danebod K; Jensen DV; Nordin H; Dalgaard EB; Chrysidis S; Kristensen S; Raun JL; Lindegaard H; Manilo N; Jakobsen SH; Hansen IMJ; Dalsgaard Pedersen D; Sørensen IJ; Andersen LS; Grydehøj J; Mehnert F; Krogh NS; Hetland ML
Ann Rheum Dis; 2019 Feb; 78(2):192-200. PubMed ID: 30396903
[TBL] [Abstract][Full Text] [Related]
19. Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study.
Egeth M; Soosaar J; Nash P; Choquette D; Infante R; Ramey DR; Sahakian S; Lai A; Kim JJ; Wu D
Adv Ther; 2017 May; 34(5):1157-1172. PubMed ID: 28417318
[TBL] [Abstract][Full Text] [Related]
20. Lower injection-site reactions and long-term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113: Results from a post-hoc analysis of a double-blind, randomized, phase III comparative study and its open-label extension in patients with rheumatoid arthritis.
Yamanaka H; Tanaka Y; Hibino T; Unmesh G; Shah C; Bakhle D; Stefanidis D
Int J Rheum Dis; 2023 Jan; 26(1):108-115. PubMed ID: 36253032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
